Pasireotide Research for Cushing's Disease
An evidence-based overview of research examining Pasireotide in the context of cushing's disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Pasireotide is FDA-approved for Cushing's disease, the first medical therapy specifically approved for this indication (2012). Phase 3 trial (N=162) demonstrated 26.3% UFC normalization at 6 months. Long-term extensions show sustained efficacy in responders for up to 5 years. Works by suppressing ACTH secretion from corticotroph adenomas via SSTR5.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Pasireotide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.